Exagen appoints former Silk Road Medical CEO Chas McKhann to Board

EXAGEN INC.

Chas McKhann appointed Class III director effective July 17, 2025; term expiring at 2028 annual meeting.
Previously served as President/CEO of Silk Road Medical and Apollo Endosurgery, both acquired by Boston Scientific.
Board size increased from 7 to 8 members; McKhann also joins Compensation and Nominating Committees.
McKhann received 7,500 RSUs vesting over 4 years; annual option for 9,000 shares under amended compensation plan.
Board approved amended non-employee director compensation program effective July 17, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.